Prior to infection, A549 cells were treated with RAB11A-specific siRNAs or Non-Target (NT) siRNAs, and RAB11A knock-down efficiency was confirmed by western blot analysis (S6C Fig) and by immunofluorescence (Figs 2A and S6A). The gene discussed is RAB11A; the disease is infection.